NCT05652920 - Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

December 15, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Hepatocellular Carcinoma

Interventions

BIOLOGICAL

Ori-C101

Hepatic arterial infusion

Trial Locations (7)

RECRUITING

Peking University Cancer Hospital, Beijing

RECRUITING

Hunan Cancer Hospital, Changsha

RECRUITING

The first hospital of Jilin University, Changchun

RECRUITING

West China Hospital, Chengdu

RECRUITING

Sir Run Run Shaw Hospital, Hangzhou

RECRUITING

Lishui Central Hospital, Lishui

RECRUITING

Zhongshan Hospital Fudan University, Shanghai